| Year |
Citation |
Score |
| 2019 |
Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, Wagner DA, West KA, Degar AJ, Brennan AM, Miller PF. An engineered Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Science Translational Medicine. 11. PMID 30651324 DOI: 10.1126/Scitranslmed.Aau7975 |
0.306 |
|
| 2019 |
Arroyo S, Tiessen RG, Denney WS, Jin J, van Iersel MP(, Zeitz H, Manning AM, Schipperus MR, Bussel JB. Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Blood. 134: 1090-1090. DOI: 10.1182/Blood-2019-125993 |
0.333 |
|
| 2015 |
Nayak S, Lee D, Arkin S, Martin SW, Heatherington AC, Denney WS, Vicini P, Hua F. A Quantitative Systems Pharmacology Model for the Coagulation Network Describes Biomarker Changes Observed in a Clinical Study with FXa Variant and Predicts Age-Associated Biomarker Variations Blood. 126: 3502-3502. DOI: 10.1182/Blood.V126.23.3502.3502 |
0.333 |
|
| 2014 |
Sharma R, Litchfield J, Atkinson K, Eng H, Amin NB, Denney WS, Pettersen JC, Goosen TC, Di L, Lee E, Pfefferkorn JA, Dalvie DK, Kalgutkar AS. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1926-39. PMID 25142735 DOI: 10.1124/Dmd.114.060087 |
0.315 |
|
| 2012 |
Reitman ML, Dishy V, Moreau A, Denney WS, Liu C, Kraft WK, Mejia AV, Matson MA, Stoch SA, Wagner JA, Lai E. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. Journal of Clinical Pharmacology. 52: 1306-16. PMID 22162541 DOI: 10.1177/0091270011419854 |
0.315 |
|
| 2010 |
Chatterjee MS, Denney WS, Jing H, Diamond SL. Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. Plos Computational Biology. 6. PMID 20941387 DOI: 10.1371/Journal.Pcbi.1000950 |
0.728 |
|
| 2010 |
Sinclair SR, Kane SA, Van der Schueren BJ, Xiao A, Willson KJ, Boyle J, de Lepeleire I, Xu Y, Hickey L, Denney WS, Li CC, Palcza J, Vanmolkot FH, Depré M, Van Hecken A, et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). British Journal of Clinical Pharmacology. 69: 15-22. PMID 20078608 DOI: 10.1111/J.1365-2125.2009.03543.X |
0.359 |
|
| 2008 |
Okorie UM, Denney WS, Chatterjee MS, Neeves KB, Diamond SL. Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow. Blood. 111: 3507-13. PMID 18203955 DOI: 10.1182/Blood-2007-08-106229 |
0.619 |
|
| 2006 |
Gosalia DN, Denney WS, Salisbury CM, Ellman JA, Diamond SL. Functional phenotyping of human plasma using a 361-fluorogenic substrate biosensing microarray. Biotechnology and Bioengineering. 94: 1099-110. PMID 16575920 DOI: 10.1002/Bit.20927 |
0.702 |
|
| 2005 |
Lo K, Denney WS, Diamond SL. Stochastic modeling of blood coagulation initiation. Pathophysiology of Haemostasis and Thrombosis. 34: 80-90. PMID 16432310 DOI: 10.1159/000089929 |
0.681 |
|
| 2005 |
Edmondson KE, Denney WS, Diamond SL. Neutrophil-bead collision assay: pharmacologically induced changes in membrane mechanics regulate the PSGL-1/P-selectin adhesion lifetime. Biophysical Journal. 89: 3603-14. PMID 16100264 DOI: 10.1529/Biophysj.105.066134 |
0.629 |
|
| 2005 |
Denney WS, Lo K, Diamond SL. Stochastic modeling of extrinsic blood coagulation dynamics Aiche Annual Meeting, Conference Proceedings. 8744. |
0.539 |
|
| 2005 |
Gosalia DN, Denney WS, Salisbury C, Ellman J, Diamond SL. Enzyme assay microarrays for biomarker detection Aiche Annual Meeting, Conference Proceedings. 8959. |
0.713 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2009 |
Gibson CR, Bergman A, Lu P, Kesisoglou F, Denney WS, Mulrooney E. Prediction of Phase i single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling Xenobiotica. 39: 637-648. PMID 19480559 DOI: 10.1080/00498250902954296 |
0.289 |
|
| 2015 |
Li CC, Vermeersch S, Denney WS, Kennedy WP, Palcza J, Gipson A, Han TH, Blanchard R, De Lepeleire I, Depré M, Murphy MG, Van Dyck K, de Hoon JN. Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist. British Journal of Clinical Pharmacology. 79: 831-7. PMID 25377933 DOI: 10.1111/Bcp.12547 |
0.261 |
|
| 2014 |
Peng JZ, Denney WS, Musser BJ, Liu R, Tsai K, Fang L, Reitman ML, Troyer MD, Engel SS, Xu L, Stoch A, Stone JA, Kowalski KG. A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. The Aaps Journal. 16: 1259-70. PMID 25160589 DOI: 10.1208/S12248-014-9648-X |
0.252 |
|
| 2016 |
Denney WS, Denham DS, Riggs MR, Amin NB. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study. Clinical Pharmacology in Drug Development. 5: 517-527. PMID 27870481 DOI: 10.1002/Cpdd.261 |
0.252 |
|
| 2017 |
Kurtz C, Denney WS, Blankstein L, Guilmain SE, Machinani S, Kotula J, Saha S, Miller P, Brennan AM. Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates. Clinical and Translational Science. PMID 29194983 DOI: 10.1111/Cts.12528 |
0.242 |
|
| 2015 |
Amin NB, Aggarwal N, Pall D, Paragh G, Denney WS, Le V, Riggs M, Calle RA. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes, Obesity & Metabolism. 17: 751-9. PMID 25885172 DOI: 10.1111/Dom.12474 |
0.236 |
|
| 2014 |
Conrado DJ, Denney WS, Chen D, Ito K. An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics. 41: 581-98. PMID 25168488 DOI: 10.1007/S10928-014-9375-Z |
0.227 |
|
| 2018 |
Puurunen M, Denney W, Blankstein L, Goldwater R, Parsons T, Millet Y, Kurtz C, Brennan A. Tolerabilityand kinetics of SYNB1020 in a Phase 1, first-in-Human, healthy adult volunteer study Journal of Hepatology. 68: S737. DOI: 10.1016/S0168-8278(18)31735-5 |
0.223 |
|
| 2021 |
Charbonneau MR, Denney WS, Horvath NG, Cantarella P, Castillo MJ, Puurunen MK, Brennan AM. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria. Communications Biology. 4: 898. PMID 34294862 DOI: 10.1038/s42003-021-02183-1 |
0.221 |
|
| 2019 |
Siebenga PS, van Amerongen G, Okkerse P, Denney WS, Dua P, Butt RP, Hay JL, Groeneveld GJ. Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs. European Journal of Pain (London, England). PMID 30793411 DOI: 10.1002/Ejp.1379 |
0.219 |
|
| 2016 |
Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. British Journal of Clinical Pharmacology. PMID 27621150 DOI: 10.1111/Bcp.13127 |
0.207 |
|
| 2019 |
Bajaj JS, Bloom PP, Chung RT, Hassanein TI, Padilla-Martinez M, Kayali Z, Rockey DC, Sasso R, Muthukumar AR, Lee WM, Denney WS, Gavis EA, Anderson C, Blankstein L, Brennan AM, et al. Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. The American Journal of Gastroenterology. PMID 31449156 DOI: 10.14309/Ajg.0000000000000384 |
0.195 |
|
| 2024 |
Perreault M, Means J, Gerson E, James M, Cotton S, Bergeron CG, Simon M, Carlin DA, Schmidt N, Moore TC, Blasbalg J, Sondheimer N, Ndugga-Kabuye K, Denney WS, Isabella VM, et al. The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers. Cell Host & Microbe. PMID 38309259 DOI: 10.1016/j.chom.2024.01.005 |
0.193 |
|
| 2021 |
Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, et al. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature Metabolism. PMID 34294923 DOI: 10.1038/s42255-021-00430-7 |
0.16 |
|
| 2023 |
Vockley J, Sondheimer N, Puurunen M, Diaz GA, Ginevic I, Grange DK, Harding C, Northrup H, Phillips JA, Searle S, Thomas JA, Zori R, Denney WS, Ernst SL, Humphreys K, et al. Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial. Nature Metabolism. PMID 37770764 DOI: 10.1038/s42255-023-00897-6 |
0.159 |
|
| 2021 |
Shane SE, Langston VC, Wills RW, Denney WS, Knych H, Fontenot RL, Meyer RE, Natalini CC. Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. Journal of Veterinary Pharmacology and Therapeutics. PMID 33576078 DOI: 10.1111/jvp.12951 |
0.143 |
|
| 2024 |
Leu JH, Vermeulen A, Abbes C, Arroyo S, Denney WS, Ling LE. Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study. Frontiers in Neuroscience. 18: 1302714. PMID 38362023 DOI: 10.3389/fnins.2024.1302714 |
0.123 |
|
| 2020 |
Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Reports. Medicine. 1: 100057. PMID 33205064 DOI: 10.1016/j.xcrm.2020.100057 |
0.121 |
|
| 2022 |
Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, et al. Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature Metabolism. PMID 35974248 DOI: 10.1038/s42255-022-00635-4 |
0.04 |
|
| 2012 |
Denney W, Ahmad N, Dillard B, Nowicki MJ. Children will eat the strangest things: a 10-year retrospective analysis of foreign body and caustic ingestions from a single academic center. Pediatric Emergency Care. 28: 731-4. PMID 22858742 DOI: 10.1097/PEC.0b013e31826248eb |
0.034 |
|
| Hide low-probability matches. |